Phapros Tbk partners with Anugrah Argon Medica to strengthen drug distribution in Indonesia.

JAKARTA, August 8th, 2022 - The significant growth of the pharmaceutical industry in Indonesia has encouraged many drug manufacturers to expand their distribution networks. As one of the state-owned enterprises' subsidiaries, PT Phapros Tbk officially partnered with Anugrah Argon Medica (AAM) this August, which is one of the Top 3 pharmaceutical product distributors in Indonesia. The collaboration was marked by the signing of an agreement between Phapros (PEHA) and AAM on Monday (8/8) at the Phapros office in Mega Kuningan area, South Jakarta.

According to Phapros Marketing Director Imelda Alini Pohan, Phapros aims to expand the distribution of its products to make them easily accessible to the public, especially in previously hard-to-reach areas due to limited supply chain networks, infrastructure access, and logistics issues. "We want medication fulfillment for the public to reach even the most remote areas, and this is our responsibility as a national pharmaceutical company," Imelda said during the signing.

Distribution is a crucial key to an industry to make its production accessible to the public wherever they are. In this regard, Imelda added that Phapros pays close attention to its distribution chain so that Phapros' drugs and medical equipment produced through a long process and strict quality control can be accessible to all regions in Indonesia. "Currently, PEHA has collaborated with large distributors and branch networks that spread throughout Indonesia, such as Kimia Farma Trading & Distribution, Rajawali Nusindo, and now AAM. We hope our products will be more accessible through this additional collaboration, and we are committed to trying our best to meet the needs of the public," she added.

Previously, Phapros' performance in H1/2022 showed positive sales growth. The newly released financial report by PEHA noted a sales growth of 21 percent, higher than the same period in 2021. "This is an indication that some of our strategies throughout 2022 have worked quite well. The key to adapting and innovating in all aspects of business, both operational and supporting, must continue to be improved so that the public's expectation of the accessibility of Phapros products in Indonesia can be realized to their nearest healthcare facilities, pharmacies, and drugstores," Imelda concluded.

In addition to sales, Phapros' positive performance in the first six months of 2021 was a decrease in the company's long-term liability ratio by 6 percent compared to last year. Meanwhile, from the current period's profit side, Phapros also recorded an increase of 7 percent compared to 2021, as well as an 8 percent increase in earnings per share.